Market Overview:
The global ulcerative colitis drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of ulcerative colitis, rising awareness about the disease, and technological advancements in the field of drug development. Based on type, the global ulcerative colitis drugs market is segmented into oral and injection segments. The oral segment is expected to dominate this market during the forecast period owing to its high adoption rate among patients suffering from ulcerative colitis. By application, this market is segmented into hospital and drug stores segments. The hospital segment dominates this market due to increased use of these drugs for treating severe cases of ulcerative colitis in hospitals across the globe.
Product Definition:
Ulcerative Colitis Drugs are used to treat the symptoms of Ulcerative Colitis, a chronic inflammatory bowel disease.
Oral:
Oral treatment for ulcerative colitis includes drugs that are taken by mouth. The majority of the drugs used for UC are anti-integrin agents such as 5-aminolevulinic acid (5-ALA) and 5-fluorouracil. Some other drug classes used to treat ulcerative colitis include corticosteroids, immunosuppressants, monoclonal antibodies, and biologic response modifiers.
Injection:
Injection is a medical procedure used to deliver medication into the body. Medication injected by doctors or pharmacists is known as Injection. There are two types of injections, interventional and therapeutic (injectable). Interventional injection consists of diagnostic or therapeutic drugs that are administered to diagnose, treat, or prevent a disease condition. Therapeutic injection consists of drugs that help in healing ulcerative colitis and other related diseases like Crohn's Disease & cancer among others.
Application Insights:
The drugs stores application segment held the largest share of 77.4% in 2017 owing to high prevalence of ulcerative colitis and increasing healthcare awareness among people, especially in developing countries including India, China and Brazil. The hospital application segment is expected to witness fastest growth at a CAGR of XX% from 2018 to 2030 due to growing number of hospitals & surgeries across the globe as well as rising healthcare expenditure globally.
Infectious diseases are one of the major causes for long-term disability around the world with more than USD 250 billion spent annually on infectious disease treatment and management which accounts for nearly 9% of total global health expenditure in 2015 according to WHO data. Thus, increasing incidence rateof different typesof chronic infections coupled with a rise in demandfor effective antibiotic treatments is anticipatedto boost industry growth over the forecast period (2030).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to presence of key companies, such as Johnson & Johnson; Merck & Co., Inc.; and AbbVie, Inc. Moreover, increasing prevalence of ulcerative colitis and better healthcare facilities are some factors attributing toward the growth of this regional segment.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising geriatric population base coupled with increasing disposable income levels in emerging economies such as India and China. In addition, growing awareness about available treatment options for UC is also expected favorably impact overall market development during the estimated time span.
Growth Factors:
- Increasing incidence of Ulcerative Colitis
- Growing awareness about Ulcerative Colitis Drugs
- Rising demand for better treatment options for Ulcerative Colitis
- Technological advancements in the field of Ulcerative Colitis Drugs
- Availability of government funding and support for research and development
Scope Of The Report
Report Attributes
Report Details
Report Title
Ulcerative Colitis Drugs Market Research Report
By Type
Oral, Injection
By Application
Hospital, Drugs Stores
By Companies
Johnson & Johnson., AbbVie, Takeda Pharmaceuticals, Roche, Warner Chilcott, Salix Pharmaceuticals/Santarus, Takeda, Ferring Pharmaceuticals, Pfizer, InDeX Pharmaceuticals, Johnson & Johnson.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Ulcerative Colitis Drugs Market Report Segments:
The global Ulcerative Colitis Drugs market is segmented on the basis of:
Types
Oral, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Stores
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson.
- AbbVie
- Takeda Pharmaceuticals
- Roche
- Warner Chilcott
- Salix Pharmaceuticals/Santarus
- Takeda
- Ferring Pharmaceuticals
- Pfizer
- InDeX Pharmaceuticals
- Johnson & Johnson.
Highlights of The Ulcerative Colitis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- By Application:
- Hospital
- Drugs Stores
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ulcerative Colitis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ulcerative colitis drugs are medications used to treat ulcerative colitis. These medications help to relieve symptoms such as diarrhea, abdominal pain, and fatigue. Some of the most common ulcerative colitis drugs include mesalamine (Asacol), sulfasalazine (Azulfidine), and 5-aminosalicylic acid (5-ASA).
Some of the major companies in the ulcerative colitis drugs market are Johnson & Johnson., AbbVie, Takeda Pharmaceuticals, Roche, Warner Chilcott, Salix Pharmaceuticals/Santarus, Takeda, Ferring Pharmaceuticals, Pfizer, InDeX Pharmaceuticals, Johnson & Johnson..
The ulcerative colitis drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ulcerative Colitis Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ulcerative Colitis Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ulcerative Colitis Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ulcerative Colitis Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ulcerative Colitis Drugs Market Size & Forecast, 2020-2028
4.5.1 Ulcerative Colitis Drugs Market Size and Y-o-Y Growth
4.5.2 Ulcerative Colitis Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Stores
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ulcerative Colitis Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ulcerative Colitis Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Stores
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Stores
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Stores
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Stores
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Stores
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ulcerative Colitis Drugs Market: Competitive Dashboard
14.2 Global Ulcerative Colitis Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson.
14.3.2 AbbVie
14.3.3 Takeda Pharmaceuticals
14.3.4 Roche
14.3.5 Warner Chilcott
14.3.6 Salix Pharmaceuticals/Santarus
14.3.7 Takeda
14.3.8 Ferring Pharmaceuticals
14.3.9 Pfizer
14.3.10 InDeX Pharmaceuticals
14.3.11 Johnson & Johnson.
